-
Bayer Has Paid $1.143 Billion To Settle 3,058 Baycol Cases
October 2005 Baycol / Lipobay Settlement Update From Bayer In the first part of November 2005 Bayer AG said that it has paid $1.143 billion to settle 3,058 Baycol / Lipobay cases worldwide. Further,…
-
3600 Hormone Replacement Therapy Drug Lawsuits Filed Since 2002 Study
Do Hormone Drugs Cause Cancer? First Federal Court Trial Set For July On July 9, 2002 a major study of hormone-replacement drugs for menopausal women was halted after finding a possible association between the…
-
AstraZeneca Proposes Early FDA Review For All Prescription Drug Ads
Direct-to-consumer Advertisements Would Be Reviewed Prior To First Use The drug company AstraZeneca Plc has proposed that there be a mandatory FDA review of all direct-to-consumer ("DTC") advertisements for prescription drugs before the ad…
-
Merck’s General Counsel Comments On Humeston Vioxx Verdict in NJ
Kenneth Frazier: Merck’s Vioxx Strategy Is To Defend Each Case, Not Settle On November 3, 2005, Merck’s General Counsel Kenneth Frazier commented on the New Jersey Vioxx defense verdict in the Humeston v. Merck…
-
New Study Suggests Tysabri Not Likely Come Back On Market
FDA Will Determine Whether Risks Outweigh Any Potential Benefit Serious side effects associated with Tysabri may outweigh any potential benefit, according to a study published in early November 2005, such that the once-promising drug…
-
Merck Prevails In Its First New Jersey Vioxx Trial
Humeston Case Ends with Defense Verdict for Merck Merck & Co. got what it wanted in its first New Jersey Vioxx trial: a defense verdict. On November 3, 2005, a New Jersey state court…
